Related Experiment Video

Updated: Aug 25, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Amnestic MCI or prodromal Alzheimer's disease?

Bruno Dubois1, Martin L Albert

  • 1Fédération de Neurologie and Inserm E007, Hôpital de la Salpêtrière, Paris, France. b.dubois@psl.ap-hop-paris.fr

The Lancet. Neurology
|March 25, 2004
PubMed

Insights

Mild cognitive impairment (MCI) encompasses diverse conditions. Early identification of underlying causes, like Alzheimer's disease (AD), is becoming possible through advanced assessments, enabling diagnosis of "prodromal AD".

Area of Science:

  • Neurology
  • Gerontology
  • Neuroscience

Background:

  • Mild cognitive impairment (MCI) is a heterogeneous condition characterized by cognitive changes not meeting dementia criteria.
  • Current diagnostic approaches for MCI encompass a wide range of pathological disorders, leading to patient diversity in memory clinics.
  • The heterogeneity of MCI poses challenges for targeted treatment and understanding disease progression.

Purpose of the Study:

  • To address the underlying heterogeneity within mild cognitive impairment (MCI).
  • To propose that identifying specific pathological disorders in MCI patients before dementia onset is increasingly feasible.
  • To introduce diagnostic criteria for "prodromal Alzheimer's disease" (AD).

Main Methods:

  • Utilizing specific neuropsychological assessments.
  • Employing advanced neuroimaging techniques.
  • Analyzing relevant biomarkers for disease identification.

Main Results:

  • Patients with Alzheimer's disease (AD), a significant MCI subgroup, can be identified prior to the full dementia syndrome.
  • The proposed diagnostic criteria aim to differentiate prodromal AD from other causes of MCI.
  • The study suggests a shift towards earlier etiological diagnosis in cognitive impairment.

Conclusions:

  • It is becoming possible to identify the specific pathological disorders underlying MCI.
  • Early diagnosis of conditions like Alzheimer's disease (AD) is crucial for timely intervention.
  • The development of criteria for "prodromal AD" represents a significant advancement in cognitive neurology.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-145105:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Amnesia01:13

Amnesia

Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...